Sign In
Buy SOLV
$74.56
-2.00 (-2.61%)
At Close: Jun 17, 2026
Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025
04:05pm, Thursday, 17'th Jul 2025
ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close
Is the Options Market Predicting a Spike in Solventum Stock?
10:01am, Monday, 07'th Jul 2025
Investors need to pay close attention to SOLV stock based on the movements in the options market lately.
Solventum Named a Best Company to Work for by U.S. News & World Report
10:00am, Wednesday, 18'th Jun 2025
Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of
Solventum to Participate in the 2025 Goldman Sachs Health Care Conference
04:05pm, Tuesday, 03'rd Jun 2025
ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
12:16pm, Tuesday, 03'rd Jun 2025
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Solventum (SOLV) Just Overtook the 200-Day Moving Average
10:30am, Monday, 12'th May 2025
Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a lon
Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript
05:07pm, Sunday, 11'th May 2025
Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communicati
Solventum Corporation: Cheap, With Caveats
11:02am, Friday, 09'th May 2025
Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solut
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
10:46am, Friday, 09'th May 2025
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
06:31pm, Thursday, 08'th May 2025
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stree
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
06:20pm, Thursday, 08'th May 2025
Solventum (SOLV) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $2.08 per share a year ago.
Solventum beats first-quarter profit estimates on strong surgical product sales
06:11pm, Thursday, 08'th May 2025
3M spin-off Solventum beat analysts' estimate for first-quarter profit on Thursday, helped by higher sales of its wound care, sterilization products.
Solventum Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
Reported sales increased 2.6%; organic sales increased 4.3% Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5% ST. PAUL, Minn.
Solventum to Participate in the 2025 BofA Securities Health Care Conference
04:05pm, Thursday, 08'th May 2025
ST. PAUL, Minn. , May 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday,
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
02:10pm, Wednesday, 07'th May 2025
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
